Smruthy Sivakumar
Overview
Explore the profile of Smruthy Sivakumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
332
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mechahougui H, Hildebrand L, Haberberger J, Sivakumar S, Saiji E, Tukachinsky H, et al.
Lab Invest
. 2025 Feb;
105(5):104116.
PMID: 39984125
Treatment for gastrointestinal stromal tumor (GIST) focuses on tyrosine kinase inhibitors, the selection of which depends on specific mutations. We sought to determine the clinical use of liquid biopsy in...
2.
Ozgu E, Kaplan B, Sivakumar S, Sokol E, Aydin E, Tokat U, et al.
BJC Rep
. 2024 Nov;
2(1):77.
PMID: 39516363
Background: Kinase-impaired class III BRAF mutations have recently received attention as a possible prognostic factor and therapeutic target. Class III BRAF variants differ from class I and class II mutations...
3.
Basin M, Miguel C, Jacob J, Goldberg H, Grivas P, Spiess P, et al.
Target Oncol
. 2024 Oct;
19(6):981-990.
PMID: 39369133
Background: Tumors harboring two or more PIK3CA short variant (SV) ("multi-hit") mutations have been linked to improved outcomes with anti-PIK3CA-targeted therapies in breast cancer. The landscape and clinical implications of...
4.
Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, et al.
J Natl Compr Canc Netw
. 2024 Aug;
22(7).
PMID: 39116914
Background: Some genomic alterations in non-small cell lung cancer (NSCLC) are known to differ according to race, sex, or age. These studies have been limited in sample size and thus...
5.
Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman A, Bektas A, et al.
J Clin Oncol
. 2024 Jul;
42(28):3339-3349.
PMID: 39038258
PURPOSEThe impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non-small-cell lung cancer (NSCLC) is unknown. Preclinically, intratumoral Escherichia is associated with a proinflammatory tumor...
6.
Sisoudiya S, Houle A, Fernando T, Wilson T, Schutzman J, Lee J, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):153.
PMID: 39033203
Racial/ethnic disparities mar NSCLC care and treatment outcomes. While socioeconomic factors and access to healthcare are important drivers of NSCLC disparities, a deeper understanding of genetic ancestry-associated genomic landscapes can...
7.
Choi Y, Dharia N, Jun T, Chang J, Royer-Joo S, Yau K, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3788-3797.
PMID: 38995268
Purpose: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS...
8.
Posada J, Yakirevich E, Kamat A, Sood A, Jacob J, Bratslavsky G, et al.
Mod Pathol
. 2024 Jan;
37(3):100424.
PMID: 38219954
The micropapillary subtype of urothelial carcinoma (MPUC) of the bladder is a very aggressive histological variant of urothelial bladder cancer (UBC). A high frequency of MPUC contains activating mutations in...
9.
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, et al.
Breast Cancer Res Treat
. 2023 Nov;
204(1):181-185.
PMID: 37999916
Purpose: Approximately 5% of breast cancers each year are diagnosed in young women < 40 years who tend to have worse clinical outcomes. We compared genomic alterations using comprehensive genomic...
10.
Porta C, Pradelli L, Sicari E, Castellani S, Sivakumar S, Sokol E, et al.
Lung Cancer
. 2023 Sep;
185:107359.
PMID: 37703610
Objectives: Liquid biopsy with next-generation sequencing (NGS) has emerged as a promising tool for tumor mutation profiling. In this study, we describe the genomic profile of Italian lung cancer patients...